Skip to content

Deutetrabenazine

VMAT2 inhibitor • Last reviewed 2025-09-26

Brands: Austedo

Sources updated 2025 • 1 references

Summary

General Information

Indicated for: Tardive dyskinesia; chorea associated with Huntington disease. VMAT2 inhibitor

Dosage & Administration

Typical dose range: 24–48 mg/day

Indications (label)

Tardive dyskinesia; chorea associated with Huntington disease.

View labelExact

Mechanism (brief)

VMAT2 inhibitor that reduces presynaptic dopamine packaging.

Metabolism & Half‑life

  • Metabolism: CYP2D6 to active metabolites.
  • Half‑life: ~9–10 h.

Therapeutic Drug Monitoring (TDM)

Recommended: No

References